New treatments for influenza

BMC Medicine

Sailen Barik¹ 

[1] Center for Gene Regulation in Health and Disease, Cleveland State University, 2351 Euclid Avenue, Cleveland, Ohio 44115, USA

关键词: zanamivir;    siRNA;    oseltamivir;    NSAID;    neuraminidase;    hemagglutinin;    influenza;    defensin;    Cathelicidin;   

Others  :  857353
DOI  :  10.1186/1741-7015-10-104

 received in 2012-04-24, accepted in 2012-09-13,  发布年份 2012

【 摘 要 】

Influenza has a long history of causing morbidity and mortality in the human population through routine seasonal spread and global pandemics. The high mutation rate of the RNA genome of the influenza virus, combined with assortment of its multiple genomic segments, promote antigenic diversity and new subtypes, allowing the virus to evade vaccines and become resistant to antiviral drugs. There is thus a continuing need for new anti-influenza therapy using novel targets and creative strategies. In this review, we summarize prospective future therapeutic regimens based on recent molecular and genomic discoveries.

【 授权许可】

   
2012 Barik; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]WHO: Influenza (seasonal). [http://www.who.int/mediacentre/factsheets/fs211/en/] webcite 2009.
• [2]Metersky ML, Masterton RG, Lode H, File TM Jr, Babinchak T: Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis 2012, 16:e321-331.
• [3]Hale BG, Albrecht RA, García-Sastre A: Innate immune evasion strategies of influenza viruses. Future Microbiol 2010, 5:23-41.
• [4]Palese P, Shaw ML: Orthomyxoviridae: the viruses and their replication. In Fields Virology. 5th edition. Edited by Knipe DM, Howley PM. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:1647-1689.
• [5]Morens DM, Taubenberger JK, Fauci AS: Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008, 198:962-970.
• [6]Haessler S, Paez A, Rothberg M, Higgins T: 2009 pandemic H1N1-associated myocarditis in a previously healthy adult. Clin Microbiol Infect 2011, 17:572-574.
• [7]Kumar K, Guirgis M, Zieroth S, Lo E, Menkis AH, Arora RC, Freed DH: Influenza myocarditis and myositis: case presentation and review of the literature. Can J Cardiol 2011, 27:514-522.
• [8]Pan HY, Yamada H, Chida J, Wang S, Yano M, Yao M, Zhu J, Kido H: Up-regulation of ectopic trypsins in the myocardium by influenza A virus infection triggers acute myocarditis. Cardiovasc Res 2011, 89:595-603.
• [9]Ru YX, Li YC, Zhao Y, Zhao SX, Yang JP, Zhang HM, Pang TX: Multiple organ invasion by viruses: pathological characteristics in three fatal cases of the 2009 pandemic influenza A/H1N1. Ultrastruct Pathol 2011, 35:155-161.
• [10]Toffan A, Serena Beato M, De Nardi R, Bertoli E, Salviato A, Cattoli G, Terregino C, Capua I: Conventional inactivated bivalent H5/H7 vaccine prevents viral localization in muscles of turkeys infected experimentally with low pathogenic avian influenza and highly pathogenic avian influenza H7N1 isolates. Avian Pathol 2008, 37:407-412.
• [11]Bitko V, Musiyenko A, Barik S: Viral infection of the lungs through the eye. J Virol 2007, 81:783-790.
• [12]Chen W, Calvo PA, Malide D, Gibbs J, Schubert U, Bacik I, Basta S, O'Neill R, Schickli J, Palese P, Henklein P, Bennink JR, Yewdell JW: A novel influenza A virus mitochondrial protein that induces cell death. Nat Med 2001, 7:1306-1312.
• [13]Krug RM, Aramini JM: Emerging antiviral targets for influenza A virus. Trends Pharmacol Sci 2009, 30:269-277.
• [14]Marazzi I, Ho JS, Kim J, Manicassamy B, Dewell S, Albrecht RA, Seibert CW, Schaefer U, Jeffrey KL, Prinjha RK, Lee K, García-Sastre A, Roeder RG, Tarakhovsky A: Suppression of the antiviral response by an influenza histone mimic. Nature 2012, 483:428-433.
• [15]Munir M, Zohari S, Belák S, Berg M: Double-stranded RNA-induced activation of activating protein-1 promoter is differentially regulated by the non-structural protein 1 of avian influenza A viruses. Viral Immunol 2012, 25:79-85.
• [16]Lin L, Li Y, Pyo HM, Lu X, Raman SN, Liu Q, Brown EG, Zhou Y: Identification of RNA helicase A as a cellular factor that interacts with influenza A virus NS1 protein and its role in the virus life cycle. J Virol 2012, 86:1942-1954.
• [17]Golebiewski L, Liu H, Javier RT, Rice AP: The avian influenza virus NS1 ESEV PDZ binding motif associates with Dlg1 and Scribble to disrupt cellular tight junctions. J Virol 2011, 85:10639-10648.
• [18]Billharz R, Zeng H, Proll SC, Korth MJ, Lederer S, Albrecht R, Goodman AG, Rosenzweig E, Tumpey TM, García-Sastre A, Katz M: The NS1 protein of the 1918 pandemic influenza virus blocks host interferon and lipid metabolism pathways. J Virol 2009, 83:10557-10570.
• [19]Kochs G, García-Sastre A, Martínez-Sobrido L: Multiple anti-interferon actions of the influenza A virus NS1 protein. J Virol 2007, 81:7011-7021.
• [20]Gack MU, Albrecht RA, Urano T, Inn KS, Huang IC, Carnero E, Farzan M, Inoue S, Jung JU, García-Sastre A: Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 2009, 5:439-449.
• [21]Forbes NE, Ping J, Dankar SK, Jia JJ, Selman M, Keleta L, Zhou Y, Brown EG: Multifunctional adaptive NS1 mutations are selected upon human influenza virus evolution in the mouse. PLoS One 2012, 7:e31839.
• [22]Ayllon J, Hale BG, García-Sastre A: Strain-specific contribution of NS1-activated phosphoinositide 3-kinase signaling to influenza A virus replication and virulence. J Virol 2012, 86:5366-5370.
• [23]Noronha JM, Liu M, Squires RB, Pickett BE, Hale BG, Air GM, Galloway SE, Takimoto T, Schmolke M, Hunt V, Klem E, García-Sastre A, McGee M, Scheuermann RH: Influenza Sequence Feature Variant Type (Flu-SFVT) analysis: evidence for a role of NS1 in influenza host range restriction. J Virol 2012, 86:5857-5866.
• [24]Versteeg GA, Hale BG, van Boheemen S, Wolff T, Lenschow DJ, García-Sastre A: Species-specific antagonism of host ISGylation by the influenza B virus NS1 protein. J Virol 2010, 84:5423-5430.
• [25]Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y: Evolution and ecology of influenza A viruses. Microbiol Rev 1992, 56:152-179.
• [26]Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, Meijer A, van Steenbergen J, Fouchier R, Osterhaus A, Bosman A: Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004, 363:587-593.
• [27]Claas EC, Osterhaus AD, van Beek R, De Jong JC, Rimmelzwaan GF, Senne DA, Krauss S, Shortridge KF, Webster RG: Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998, 351:472-477.
• [28]Kuiken T, Holmes EC, McCauley J, Rimmelzwaan GF, Williams CS, Grenfell BT: Host species barriers to influenza virus infections. Science 2006, 312:394-397.
• [29]Centers for Disease Control and Prevention: Seasonal influenza (flu) - information on H3N2 variant influenza A viruses. [http://www.cdc.gov/flu/swineflu/influenza-variant-viruses-h3n2v.htm] webcite
• [30]Darwish I, Mubareka S, Liles WC: Immunomodulatory therapy for severe influenza. Expert Rev Anti Infect Ther 2011, 9:807-822.
• [31]Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG: Into the eye of the cytokine storm. Microbiol Mol Biol Rev 2012, 76:16-32.
• [32]Yuen KY, Chan PK, Peiris M, Tsang DN, Que TL, Shortridge KF, Cheung PT, To WK, Ho ET, Sung R, Cheng AF: Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998, 351:467-471.
• [33]Wong SS, Yuen KY: Avian influenza virus infections in humans. Chest 2006, 129:156-168.
• [34]Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Aavian Influenza A (H5N1) Virus, Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de J, Naghdaliyev A, Peiris JS, Shindo N, Soeroso S, Uyeki TM: Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008, 358:261-273.
• [35]Cheung CY, Poon LL, Lau AS, Luk W, Lau YL, Shortridge KF, Gordon S, Guan Y, Peiris JS: Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002, 360:1831-1837.
• [36]Ison MG, Gnann JW Jr, Nagy-Agren S, Treannor J, Paya C, Steigbigel R, Elliott M, Weiss HL, Hayden FG: Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003, 8:183-190.
• [37]Wolf YI, Viboud C, Holmes EC, Koonin EV, Lipman DJ: Long intervals of stasis punctuated by bursts of positive selection in the seasonal evolution of influenza A virus. Biol Direct 2006, 1:34. BioMed Central Full Text
• [38]Webby RJ, Webster RG: Emergence of influenza A viruses. Philos Trans R Soc Lond B Biol Sci 2001, 356:1817-1828.
• [39]Patterson KD, Pyle GF: The geography and mortality of the 1918 influenza pandemic. Bull Hist Med 1991, 65:4-21.
• [40]Taubenberger JK, Reid AH, Janczewski TA, Fanning TG: Integrating historical, clinical and molecular genetic data in order to explain the origin and virulence of the 1918 Spanish influenza virus. Philos Trans R Soc Lond B Biol Sci 2001, 356:1829-1839.
• [41]Dunham EJ, Dugan VG, Kaser EK, Perkins SE, Brown IH, Holmes EC, Taubenberger JK: Different evolutionary trajectories of European avian-like and classical swine H1N1 influenza A viruses. J Virol 2009, 83:5485-5494.
• [42]Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, Okomo-Adhiambo M, Gubareva L, Barnes J, Smith CB, Emery SL, Hillman MJ, Rivailler P, Smagala J, de Graaf M, Burke DF, Fouchier RA, Pappas C, Alpuche-Aranda CM, López-Gatell H, Olivera H, López I, Myers CA, Faix D, Blair PJ, Yu C, et al.: Antigenic and genetic characteristics of swine-origin 2009 A (H1N1) influenza viruses circulating in humans. Science 2009, 325:197-201.
• [43]Sheu TG, Fry AM, Garten RJ, Deyde VM, Shwe T, Bullion L, Peebles PJ, Li Y, Klimov AI, Gubareva LV: Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010. J Infect Dis 2011, 203:13-17.
• [44]Bolton E, Wang Y, Thiessen PA, Bryant SH: PubChem: Integrated platform of small molecules and biological activities. In Annual Reports in Computational Chemistry. Volume 4. Edited by Wheeler RA, Spellmeyer DC. Washington, DC: American Chemical Society/Elsevier; 2008::217-241.
• [45]Luo M: Influenza virus entry. Adv Exp Med Biol 2012, 726:201-221.
• [46]Das K, Aramini JM, Ma LC, Krug RM, Arnold E: Structures of influenza A proteins and insights into antiviral drug targets. Nat Struct Mol Biol 2010, 17:530-538.
• [47]von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, Van Phan T, Smythe ML, White HF, Oliver SW: Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363:418-423.
• [48]McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA: Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis 2007, 13:1354-1357.
• [49]Hurt AC, Holien JK, Parker MW, Barr IG: Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs 2009, 69:2523-2531.
• [50]Sugaya N, Ohashi Y: Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 2010, 54:2575-2582.
• [51]Ikematsu H, Kawai N: Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev Anti Infect Ther 2011, 9:851-857.
• [52]Chairat K, Tarning J, White NJ, Lindegardh N: Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. J Clin Pharmacol 2012, in press.
• [53]Richard M, Ferraris O, Erny A, Barthélémy M, Traversier A, Sabatier M, Hay A, Lin YP, Russell RJ, Lina B: Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir. Antimicrob Agents Chemother 2011, 55:2942-2952.
• [54]Meijer A, Lackenby A, Hungnes O, Lina B, van-der-Werf S, Schweiger B, Opp M, Paget J, van-de-Kassteele J, Hay A, Zambon M: Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009, 15:552-560.
• [55]Duan S, Boltz DA, Seiler P, Li J, Bragstad K, Nielsen LP, Webby RJ, Webster RG, Govorkova EA: Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog 2010, 6:e1001022.
• [56]Baranovich T, Webster RG, Govorkova EA: Fitness of neuraminidase inhibitor-resistant influenza A viruses. Curr Opin Virol 2011, 1:574-581.
• [57]Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM, Centers for Disease Control and Prevention (CDC): Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011, 60:1-24.
• [58]Vavricka CJ, Li Q, Wu Y, Qi J, Wang M, Liu Y, Gao F, Liu J, Feng E, He J, Wang J, Liu H, Jiang H, Gao GF: Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. PLoS Pathog 2011, 7:e1002249.
• [59]Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K: In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 2002, 46:977-981.
• [60]Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, Ozawa M, Furuta Y, Kawaoka Y: T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA 2010, 107:882-887.
• [61]Jones JC, Turpin EA, Bultmann H, Brandt CR, Schultz-Cherry S: Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J Virol 2006, 80:11960-11967.
• [62]Rajik M, Jahanshiri F, Omar AR, Ideris A, Hassan SS, Yusoff K: Identification and characterisation of a novel anti-viral peptide against avian influenza virus H9N2. Virol J 2009, 6:74. BioMed Central Full Text
• [63]Belser JA, Lu X, Szretter KJ, Jin X, Aschenbrenner LM, Lee A, Hawley S, Kim do H, Malakhov MP, Yu M, Fang F, Katz JM: DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 2007, 196:1493-1499.
• [64]Triana-Baltzer GB, Gubareva LV, Nicholls JM, Pearce MB, Mishin VP, Belser JA, Chen LM, Chan RW, Chan MC, Hedlund M, Larson JL, Moss RB, Katz JM, Tumpey TM, Fang F: Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS One 2009, 4:e7788.
• [65]Liao JK: Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 2002, 86:5-18.
• [66]Marz W, Koenig W: HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering? J Cardiovasc Risk 2003, 10:169-179.
• [67]Ludwig S: Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. J Antimicrob Chemother 2009, 64:1-4.
• [68]Viemann D, Schmolke M, Lueken A, Boergeling Y, Friesenhagen J, Wittkowski H, Ludwig S, Roth J: H5N1 virus activates signaling pathways in human endothelial cells resulting in a specific imbalanced inflammatory response. J Immunol 2011, 186:164-173.
• [69]Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R: Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370:1829-1839.
• [70]Fedson DS: Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis 2006, 43:199-205.
• [71]Enserink M: Infectious disease. Old drugs losing effectiveness against flu; could statins fill gap? Science 2005, 309:1976-1977.
• [72]Vandermeer ML, Thomas AR, Kamimoto L, Reingold A, Gershman K, Meek J, Farley MM, Ryan P, Lynfield R, Baumbach J, Schaffner W, Bennett N, Zansky S: Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012, 205:13-19.
• [73]Brett SJ, Myles P, Lim WS, Enstone JE, Bannister B, Semple MG, Read RC, Taylor BL, McMenamin J, Nicholson KG, Nguyen-Van-Tam JS, Openshaw PJ, Influenza Clinical Information Network (FLU-CIN): Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. PLoS One 2011, 6:e18120.
• [74]Viasus D, Paño-Pardo JR, Cordero E, Campins A, López-Medrano F, Villoslada A, Fariñas MC, Moreno A, Rodríguez-Baño J, Oteo JA, Martínez-Montauti J, Torre-Cisneros J, Segura F, Carratalà J, Novel Influenza A (H1N1) Study Group, Spanish Network for Research in Infectious Diseases: Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect 2011, 62:193-199.
• [75]De Loecker I, Preiser JC: Statins in the critically ill. Ann Intensive Care 2012, 2:19. BioMed Central Full Text
• [76]Billich A, Bornancin F, De´vay P, Mechtcheriakova D, Urtz N, and Baumruker T: Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 2003, 278:47408-47415.
• [77]Zemann B, Kinzel B, Mu¨ller M, Reuschel R, Mechtcheriakova D, Urtz N, Bornancin F, Baumruker T, Billich A: Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 2006, 107:1454-1458.
• [78]Jary E, Bee T, Walker SR, Chung SK, Seo KC, Morris JC, Don AS: Elimination of a hydroxyl group in FTY720 dramatically improves the phosphorylation rate. Mol Pharmacol 2010, 78:685-692.
• [79]Marsolais D, Hahm B, Walsh KB, Edelmann KH, McGavern D, Hatta Y, Kawaoka Y, Rosen H, Oldstone MB: A critical role for the sphingosine analog AAL-R in dampening the cytokine response during influenza virus infection. Proc Natl Acad Sci USA 2009, 106:1560-1565.
• [80]Walsh KB, Teijaro JR, Wilker PR, Jatzek A, Fremgen DM, Das SC, Watanabe T, Hatta M, Shinya K, Suresh M: Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci USA 2011, 108:12018-12023.
• [81]Hayden MS, Ghosh S: NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012, 26:203-234.
• [82]Rahman A, Fazal F: Blocking NF-κB: an inflammatory issue. Proc Am Thorac Soc 2011, 8:497-503.
• [83]Nimmerjahn F, Dudziak D, Dirmeier U, Hobom G, Riedel A, Schlee M, Staudt LM, Rosenwald A, Behrends U, Bornkamm GW, Mautner J: Active NF-kappaB signalling is a prerequisite for influenza virus infection. J Gen Virol 2004, 85:2347-2356.
• [84]Mazur I, Wurzer WJ, Ehrhardt C, Pleschka S, Puthavathana P, Silberzahn T, Wolff T, Planz O, Ludwig S: Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity. Cell Microbiol 2007, 9:1683-1694.
• [85]Pinto R, Herold S, Cakarova L, Hoegner K, Lohmeyer J, Planz O, Pleschka S: Inhibition of influenza virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo. Antiviral Res 2011, 92:45-56.
• [86]Wiesener N, Zimmer C, Jarasch-Althof N, Wutzler P, Henke A: Therapy of experimental influenza virus infection with pyrrolidine dithiocarbamate. Med Microbiol Immunol 2011, 200:115-126.
• [87]Schmolke M, Viemann D, Roth J, Ludwig S: Essential impact of NF-kappaB signaling on the H5N1 influenza A virus-induced transcriptome. J Immunol 2009, 183:5180-5189.
• [88]Wang X, Li M, Zheng H, Muster T, Palese P, Beg AA, García-Sastre A: Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon. J Virol 2000, 74:11566-11573.
• [89]Cederlund A, Gudmundsson GH, Agerberth B: Antimicrobial peptides important in innate immunity. FEBS J 2011, 278:3942-3951.
• [90]Ge Q, McManus MT, Nguyen T, Shen CH, Sharp PA, Eisen HN, Chen J: RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci USA 2003, 100:2718-2723.
• [91]Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
• [92]Bals R, Weiner DJ, Moscioni AD, Meegalla RL, Wilson JM: Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect Immun 1999, 67:6084-6089.
• [93]Bals R, Wang X, Zasloff M, Wilson JM: The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 1998, 95:9541-9546.
• [94]Barlow PG, Svoboda P, Mackellar A, Nash AA, York IA, Pohl J, Davidson DJ, Donis RO: Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One 2011, 6:e25333.
• [95]Tecle T, White MR, Gantz D, Crouch EC, Hartshorn KL: Human neutrophil defensins increase neutrophil uptake of influenza A virus and bacteria and modify virus-induced respiratory burst responses. J Immunol 2007, 178:8046-8052.
• [96]Doss M, White MR, Tecle T, Gantz D, Crouch EC, Jung G, Ruchala P, Waring AJ, Lehrer RI, Hartshorn KL: Interactions of alpha-, beta-, and theta-defensins with influenza A virus and surfactant protein D. J Immunol 2009, 182:7878-7887.
• [97]Salvatore M, Garcia-Sastre A, Ruchala P, Lehrer RI, Chang T, Klotman ME: alpha-Defensin inhibits influenza virus replication by cell-mediated mechanism(s). J Infect Dis 2007, 196:835-843.
• [98]Cole AM, Hong T, Boo LM, Nguyen T, Zhao C, Bristol G, Zack JA, Waring AJ, Yang OO, Lehrer RI: Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci USA 2002, 99:1813-1818.
• [99]Wang W, Cole AM, Hong T, Waring AJ, Lehrer RI: Retrocyclin, an antiretroviral theta-defensin, is a lectin. J Immunol 2003, 170:4708-4716.
• [100]Owen SM, Rudolph DL, Wang W, Cole AM, Waring AJ, Lal RB, Lehrer RI: RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2004, 20:1157-1165.
• [101]Leikina E, Delanoe-Ayari H, Melikov K, Cho MS, Chen A, Waring AJ, Wang W, Xie Y, Loo JA, Lehrer RI, Chernomordik LV: Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat Immunol 2005, 6:995-1001.
• [102]Doss M, Ruchala P, Tecle T, Gantz D, Verma A, Hartshorn A, Crouch EC, Luong H, Micewicz ED, Lehrer RI, Hartshorn KL: Hapivirins and diprovirins: novel θ-defensin analogs with potent activity against influenza A virus. J Immunol 2012, 188:2759-2768.
• [103]Venkataraman N, Cole AL, Ruchala P, Waring AJ, Lehrer RI, Stuchlik O, Pohl J, Cole AM: Reawakening retrocyclins: ancestral human defensins active against HIV-1. PLoS Biol 2009, 7:e95.
• [104]Lynch SR, Puglisi JD: Structure of a eukaryotic decoding region A-site RNA. J Mol Biol 2001, 306:1023-1035.
• [105]Durante-Mangoni E, Grammatikos A, Utili R, Falagas ME: Do we still need the aminoglycosides? Int J Antimicrob Agents 2009, 33:201-205.
• [106]Chroneos ZC, Sever-Chroneos Z, Shepherd VL: Pulmonary surfactant: an immunological perspective. Cell Physiol Biochem 2010, 25:13-26.
• [107]Seaton BA, Crouch EC, McCormack FX, Head JF, Hartshorn KL, Mendelsohn R: Structural determinants of pattern recognition by lung collectins. Innate Immun 2010, 16:143-150.
• [108]White MR, Crouch E, Vesona J, Tacken PJ, Batenburg JJ, Leth-Larsen R, Holmskov U, Hartshorn KL: Respiratory innate immune proteins differentially modulate the neutrophil respiratory burst response to influenza A virus. Am J Physiol Lung Cell Mol Physiol 2005, 289:L606-616.
• [109]Reading PC, Tate MD, Pickett DL, Brooks AG: Glycosylation as a target for recognition of influenza viruses by the innate immune system. Adv Exp Med Biol 2007, 598:279-292.
• [110]Tecle T, White MR, Crouch EC, Hartshorn KL: Inhibition of influenza viral neuraminidase activity by collectins. Arch Virol 2007, 152:1731-1742.
• [111]Hartshorn KL, White MR, Tecle T, Sorensen G, Holmskov U, Crouch EC: Viral aggregating and opsonizing activity in collectin trimers. Am J Physiol Lung Cell Mol Physiol 2010, 298:L79-88.
• [112]Ling MT, Tu W, Han Y, Mao H, Chong WP, Guan J, Liu M, Lam KT, Law HK, Peiris JS, Takahashi K, Lau YL: Mannose-binding lectin contributes to deleterious inflammatory response in pandemic H1N1 and avian H9N2 infection. J Infect Dis 2012, 205:44-53.
• [113]Bitko V, Barik S: Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol 2001, 1:34. BioMed Central Full Text
• [114]Bitko V, Musiyenko A, Shulyayeva O, Barik S: Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005, 11:50-55.
• [115]Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J: Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA 2004, 101:8676-8681.
• [116]Tompkins SM, Lo CY, Tumpey TM, Epstein SL: Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci USA 2004, 101:8682-8686.
• [117]Barik S: siRNA for influenza therapy. Viruses 2010, 2:1448-1457.
• [118]Zhou H, Jin M, Yu Z, Xu X, Peng Y, Wu H, Liu J, Liu H, Cao S, Chen H: Effective small interfering RNAs targeting matrix and nucleocapsid protein gene inhibit influenza A virus replication in cells and mice. Antiviral Res 2007, 76:186-193.
• [119]Zhou K, He H, Wu Y, Duan M: RNA interference of avian influenza virus H5N1 by inhibiting viral mRNA with siRNA expression plasmids. J Biotechnol 2008, 135:140-144.
• [120]Thakur N, Qureshi A, Kumar M: VIRsiRNAdb: a curated database of experimentally validated viral siRNA/shRNA. Nucleic Acids Res 2012, (40(Database)):D230-236.
• [121]Raza A, Shareef H, Salim H, Khushal R, Bokhari H: Selection of predicted siRNA as potential antiviral therapeutic agent against influenza virus. Bioinformation 2011, 6:340-343.
• [122]ElHefnawi M, Alaidi O, Mohamed N, Kamar M, El-Azab I, Zada S, Siam R: Identification of novel conserved functional motifs across most influenza A viral strains. Virol J 2011, 8:44.
• [123]ElHefnawi M, Hassan N, Kamar M, Siam R, Remoli AL, El-Azab I, AlAidy O, Marsili G, Sgarbanti M: The design of optimal therapeutic small interfering RNA molecules targeting diverse strains of influenza A virus. Bioinformatics 2011, 27:3364-3370.
• [124]Sirnaomics homepage [http://a216530356.oinsite.yh.mynet.cn/_d272035470.htm] webcite
• [125]Shaw ML: The host interactome of influenza virus presents new potential targets for antiviral drugs. Rev Med Virol 2011, 21:358-369.
• [126]MacArthur RD, Novak RM: Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 2008, 47:236-241.
• [127]Hao L, Sakurai A, Watanabe T, Sorensen E, Nidom CA, Newton MA, Ahlquist P, Kawaoka Y: Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature 2008, 454:890-893.
• [128]Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, Ryan BJ, Weyer JL, van der Weyden L, Fikrig E, Adams DJ, Xavier RJ, Farzan M, Elledge SJ: The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 2009, 139:1243-1254.
• [129]Shapira SD, Gat-Viks I, Shum BO, Dricot A, de Grace MM, Wu L, Gupta PB, Hao T, Silver SJ, Root DE, Hill DE, Regev A, Hacohen N: A physical and regulatory map of host influenza interactions reveals pathways in H1N1 infection. Cell 2009, 139:1255-1267.
• [130]Karlas A, Machuy N, Shin Y, Pleissner KP, Artarini A, Heuer D, Becker D, Khalil H, Ogilvie LA, Hess S, Mäurer AP, Müller E, Wolff T, Rudel T, Meyer TF: Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 2010, 463:818-822.
• [131]König R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, Bhattacharyya S, Alamares JG, Tscherne DM, Ortigoza MB, Liang Y, Gao Q, Andrews SE, Bandyopadhyay S, De Jesus P, Tu BP, Pache L, Shih C, Orth A, Bonamy G, Miraglia L, Ideker T, García-Sastre A, Young JA, Palese P, Shaw ML, Chanda SK: Human host factors required for influenza virus replication. Nature 2010, 463:813-817.
• [132]Münk C, Sommer AF, König R: Systems-biology approaches to discover anti-viral effectors of the human innate immune response. Viruses 2011, 3:1112-1130.
• [133]Min JY, Subbarao K: Cellular targets for influenza drugs. Nat Biotechnol 2010, 28:239-240.
• [134]Medina RA, García-Sastre A: Influenza A viruses: new research developments. Nat Rev Microbiol 2011, 9:590-603.
• [135]Müller KH, Kakkola L, Nagaraj AS, Cheltsov AV, Anastasina M, Kainov DE: Emerging cellular targets for influenza antiviral agents. Trends Pharmacol Sci 2012, 33:89-99.
• [136]Tafforeau L, Chantier T, Pradezynski F, Pellet J, Mangeot PE, Vidalain PO, Andre P, Rabourdin-Combe C, Lotteau V: Generation and comprehensive analysis of an influenza virus polymerase cellular interaction network. J Virol 2011, 85:13010-13018.
• [137]Mata MA, Satterly N, Versteeg GA, Frantz D, Wei S, Williams N, Schmolke M, Peña-Llopis S, Brugarolas J, Forst CV, White MA, García-Sastre A, Roth MG, Fontoura BM: Chemical inhibition of RNA viruses reveals REDD1 as a host defense factor. Nat Chem Biol 2011, 7:712-719.
• [138]Kao RY, Yang D, Lau LS, Tsui WH, Hu L, Dai J, Chan MP, Chan CM, Wang P, Zheng BJ, Sun J, Huang JD, Madar J, Chen G, Chen H, Guan Y, Yuen KY: Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 2010, 28:600-605.
• [139]Balannik V, Wang J, Ohigashi Y, Jing X, Magavern E, Lamb RA, Degrado WF, Pinto LH: Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus. Biochemistry 2009, 48:11872-11882.
• [140]Jablonski JJ, Basu D, Engel DA, Geysen HM: Design, synthesis, and evaluation of novel small molecule inhibitors of the influenza virus protein NS1. Bioorg Med Chem 2012, 20:487-497.
• [141]Barik S, Bitko V: Prospects of RNA interference therapy in respiratory viral diseases: update 2006. Expert Opin Biol Ther 2006, 6:1151-1160.
• [142]Bitko V, Barik S: Intranasal antisense therapy: preclinical models with a clinical future? Curr Opin Mol Ther 2007, 9:119-125.
• [143]Nguyen JT, Hoopes JD, Le MH, Smee DF, Patick AK, Faix DJ, Blair PJ, de Jong MD, Prichard MN, Went GT: Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010, 5:e9332.